Lilly Shares Soar 54% on 56% Revenue Growth and $12.8B Drug Sales
AMGN•Lilly’s shares rose 54% in nine months as revenue surged 56% year-over-year and operating margin widened to 47.3%, fueled by $12.8 billion in Mounjaro and Zepbound sales. Growth momentum strengthened with FDA approval of oral obesity drug Foundayo and acquisitions of Orna Therapeutics plus Centessa Pharmaceuticals to expand the pipeline.
1. Stock Rerating on Growth
Lilly’s shares have climbed 54% over nine months, lifting its market value past the $1 trillion mark. This rally reflects investor confidence in the company’s accelerating growth and profitability trajectory.
2. Incretin Franchise Performance
Revenue rose 56% year-over-year in the latest quarter, driven by Mounjaro and Zepbound, which combined for $12.8 billion in sales. The operating margin expanded to 47.3%, up from a three-year average of 35.3%, highlighting efficient conversion of revenue into profit.
3. Foundayo Approval Boosts Outlook
FDA approval of Foundayo marked the first launch of an oral incretin medicine with obesity as its initial indication. This positions Lilly to compete in a large weight-management market with a convenient pill format.
4. Strategic Biotech Acquisitions
Lilly agreed to acquire clinical-stage firms Orna Therapeutics and Centessa Pharmaceuticals to strengthen its pipeline beyond the incretin franchise. These deals aim to deploy current cash flow toward future growth opportunities in advanced biotechnology.
